These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20127590)

  • 1. Pearls: multiple sclerosis.
    Frohman EM; Greenberg BM
    Semin Neurol; 2010 Feb; 30(1):97-101. PubMed ID: 20127590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future treatments for relapsing-remitting multiple sclerosis.
    Birnbaum G
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [General practitioners' approach to relapsing multiple sclerosis].
    Mackowiak A; Jamart V; Donze C; Hautecoeur P;
    Rev Neurol (Paris); 2003 Feb; 159(2):196-8. PubMed ID: 12660572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relapsing-remitting inflammatory disease of the central nervous system with normal MRI: multiple sclerosis or phenocopy in a series of 15 patients].
    Lebrun C; Bourg V; Chanalet S; Chatel M
    Rev Neurol (Paris); 2003 Apr; 159(4):397-404. PubMed ID: 12773868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of multiple sclerosis relapses with immunomodulating agents.
    Johnson KP
    J Neurol Sci; 2007 May; 256 Suppl 1():S23-8. PubMed ID: 17350652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.
    Lebrun C; Debouverie M; Jeannin S; Pittion-Vouyovitch S; Bayreuther C; Berthier F
    Mult Scler; 2008 Aug; 14(7):933-9. PubMed ID: 18573824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the Swanton multiple sclerosis criteria for dissemination in space.
    Nielsen JM; Uitdehaag BM; Korteweg T; Barkhof F; Polman CH
    Mult Scler; 2010 Aug; 16(8):985-7. PubMed ID: 20547588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs and consequences of multiple sclerosis relapses: a managed care perspective.
    Morrow TJ
    J Neurol Sci; 2007 May; 256 Suppl 1():S39-44. PubMed ID: 17362995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.